Lysophosphatidylcholine (LPC) is an amphiphilic metabolite that can be produced from membrane-phospholipids by activation of phospholipase A2 (PLA2), and it accumulates in the heart during ischemia and reperfusion. It is known that LPC is an arrhythmogenic substance. Recent studies have revealed that LPC produces mechanical and metabolic derangements in perfused working rat hearts, and Ca2+-overload in isolated cardiac myocytes. Thus, LPC possesses an ischemia-like effect on the heart. LPC accumulated in the myocardium activates phospholipase A2, establishing a vicious circle; i.e. LPC itself has an ability to produce another LPC. Therefore, a drug that has an anti-LPC effect would protect or improve ischemia/reperfusion damage. This article will review the effect of LPC in relation to ischemia, and consider a possibility of developing new anti-ischemic drugs on the basis of the anti-LPC action. (Jpn Heart J 1997; 38: 11-25) Key words: Lysophosphatidylcholine, Free fatty acid, Ischemia reperfusion, anti-ischemic drugs SCHEMIA and reperfusion of the heart produce myocardial damage.
(ATP) and the other is production of free radicals. In this mini review we propose that lysophosphatidylcholine (LPC) is also one of the candidates responsible for Ca2+-overload during ischemia and reperfusion, and that substances that counteract the effect of LPC can be new anti-ischemic drugs.
WHY IS LPC IMPORTANT TO PRODUCE ISCHEMIC DAMAGE?
Chemistry of LPC: LPC is produced by activation of the enzyme phospholipase A2 (PLA2) from phosphatidylcholine, one of the major membrane-phospholipids1) (Figure 1 ). In phosphatidylcholine, the hydroxyl groups at the first and second positions of glycerol are esterified to the carboxyl groups of two longchain fatty acids (hydrocarbon tails). The hydroxyl group at the third position of the glycerol backbone is esterified to phosphoric acid to which choline is attached (polar head). The PLA2 releases a long-chain fatty acid (usually unsaturated fatty acids such as arachidonic acid) from the second position of the glycerol backbone, and the remaining structure with one hydrocarbon tail is called LPC. Therefore, one molecule of free fatty acid (FFA) and one molecule of LPC are produced from one molecule of phosphatidylcholine by activation of PLA2. LPC accumulates in the myocardium during both ischemia and reperfusion: Under physiological conditions, LPC is reacylated to form phosphatidyl- Changes in rate pressure product. b: Changes in the tissue levels of ATP, creatine phosphate (CrP), and lactate induced by ischemia and reperfusion. c: Changes in the tissue levels of free fatty acids (palmitoleic, arachidonic and stearic acids) induced by ischemia and reperfusion. In b and c, abbreviations are as follows. Non-ischemia; hearts were freeze-clamped in the absence of ischemia. Ischemia; hearts were freezeclamped immediately after the end of ischemia. Reperfusion; hearts were freezeclamped immediately after the end of reperfusion. Note that these changes are similar to those induced by exogenous LPC (see Figure 3) .
not recover or further decrease after removal of LPC. The level of lactate that has been increased by ischemia decreases after reperfusion, whereas the level of lactate that has been increased by LPC further increases after removal of LPC. i is increased, PLA2 is activated to release long-chain fatty acid that has been bound to the second position of the glycerol backbone of membrane-phospholipids. This is a possible mechanism for accumulation of FFA induced by exogenous LPC. In addition, LPC at low concentrations can directly increase the PLA2 activity.25) It is reasonable then to assume that LPC can be newly produced in the myocardium when exogenous LPC is applied to the heart . This means that exogenous LPC can accelerate the production of endogenous LPC, and therefore the deleterious effect of LPC continues for a long time because of LPC-induced LPC production. We think that this vicious circle of LPC production is responsible for the myocardial damage induced by ischemia/reperfusion . Ca2+-overload induced by LPC in isolated cardiac myocytes:
It has been demonstrated that LPC produces Ca2+-overload in isolated cardiac myocytes. 5, 6, 20, 24 14, 15) and that LPC causes long lasting bursts of Na+ influx because of prolongation of the inactivation process of the Na+ channel.16) It is possible that LPC first increases the intracellular Na+ concentration in cardiac myocytes because of inhibition of Na+-K+ ATPase and the increased burst of the Na+ currents, and then produces Ca2+-overload via the Na+/Ca2+ exchange mechanism.27) The second possible mechanism is that LPC directly increases sarcolemmal permeability to Ca2+. Our study18) has revealed that LPC increases non-selective cation current including the Na+, K+ and Ca2+ currents, but it does not increase the Cl-current in guinea-pig ventricular myocytes. The increase in the permeability to Ca2+ induced by LPC is lower than that to Na+ or [Ca2+]i induced by LPC is considered to be enough to cause myocardial cell damage. Nevertheless, it is unknown whether the LPC-induced increase in nonselective cation current is due to activation of some channel or direct effect on the membrane lipids. Because of the amphiphilic property of LPC, it is possible to assume that LPG makes a pore on the cell membrane through which ions can pass, leading to an increase in membrane permeability.28) Figure 5 summarizes the possible mechanisms of Ca2+-overload induced by LPC. LPG may directly increase [Ca2+]i via opening of the non-selective cation channel (or pore?), or indirectly increase [Ca2+]i via Na+/Ca2+ exchange system after increase in [Na+]i, which has been caused by inhibition of the Na+-K+ ATPase, modification of the voltage-dependent Na+ channel, and/or Na+ entry via the non-selective cation channel (or pore?). The effect of LPC on the Na+/ Ca2+ exchange system, however, remains to be elucidated. It is suggested that Ca2+ release induced by LPC from intracellular Ca2+ stores, such as sarcoplasmic reticulum (SR), is related to the LPG-induced increase in [Ca2+]i, because simultaneous treatment with ryanodine and thapsigargin (that inhibit the release of Ca2+ from SR) partially inhibits the degree of LPC-induced increase in [Ca2+]i.29) Furthermore, it is possible to assume that a vicious circle of accumulation of LPC accelerates the increase in [Ca2+]i, because manoalide, a PLA2 inhibitor, partially inhibits the degree of LPC-induced increase in [Ca2+]i.29) LPC may potentiate ischemic damage: Although there are some reports that LPC that has been accumulated in ischemic hearts is not responsible for both contractile dysfunction30) and Ca2+-overload through Na+/Ca2+ exchange,31) LPC may potentiate the ischemia/reperfusion damage for the following reasons. Sedlis et al.32) reported that the depressant effect of LPC on contractile function is enhanced by acidosis and free radicals, both of which are produced during myocardial ischemia and reperfusion. LPC may activate protein kinase C in the heart: Several studies suggest that LPC activates protein kinase C in the brain,33,34) T-lymphocytes35) and endothelial cells,36) and that LPC is involved in the signal transduction in these cells .33-35) In the vascular system, LPC that is contained in the oxidized low-density lipoprotein may play an important role in atherogenesis via activation of protein kinase C.36-39) In the heart, however, it is uncertain whether LPC actually activates protein kinase C or not. If LPC activates protein kinase C in the heart, it may affect signal transduction in the cardiac cells including slow response such as ventricular remodeling after myocardial infarction . It is also possible that protein kinase C is involved in the quick response in the myocardium; Ikeda et al .40) suggested that activation of protein kinase C accelerates hypoxic myocardial summarizes the effects of various drugs we examined in terms of their anti-LPC effect, voltage-dependent Na+-channel blocking action and lipophilicity. Lipophilicity is expressed as a log octanol/water coefficient. It is suggested from Table II that drugs possessing both voltage-dependent Na+-channel blocking action and high lipophilicity are necessary to inhibit the effect of LPC. This is a new approach to the development of new drugs possessing an anti-LPC effect, and this new approach may lead to the development of new anti-ischemic drugs.
In order to develop drugs possessing an anti-LPC effect, we must know the exact mechanisms of the effect of LPC and the exact role of LPC in ischemic damage. At present, however, our knowledge is still limited. Further studies are necessary to clarify the exact mechanisms of the effect of LPC and the role of LPC in ischemic damage.
Conclusion:
Evidence has indicated that LPG that accumulates in the ischemic myocardium initiates or potentiates ischemic damage. Development of drugs which can inhibit or attenuate the deleterious effect of LPC on the heart would be useful to find a more effective new drug that protects the heart against ischemic injury.
Because LPC possesses multiple effects, it may be difficult to find a drug which inhibits all the deleterious effects of LPC. Nevertheless, combination of some drugs, each of which inhibits different effects of LPC would have beneficial effects on the ischemia-reperfused heart.
